Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
Summary
This summary is machine-generated.Allogeneic bone marrow transplants in children with osteogenesis imperfecta led to functional mesenchymal progenitor cell engraftment. This approach shows promise for treating this genetic bone disorder and other mesenchymal stem cell conditions.
Area Of Science
- Regenerative Medicine
- Genetics
- Orthopedics
Background
- Mesenchymal progenitor cell transplantation could treat genetic bone disorders.
- Clinical evidence supporting this concept is currently limited.
- Osteogenesis imperfecta is a genetic disorder characterized by defective type I collagen production by osteoblasts.
Purpose Of The Study
- To evaluate the efficacy of allogeneic bone marrow transplantation in treating children with osteogenesis imperfecta.
- To assess the potential for mesenchymal progenitor cell engraftment and functional recovery.
Main Methods
- Allogeneic bone marrow transplantation was performed in three children with osteogenesis imperfecta.
- Engraftment of donor mesenchymal progenitor cells was assessed.
- Bone mineral content, growth velocity, and fracture frequency were monitored post-transplantation.
Main Results
- Successful engraftment of donor osteoblasts (1.5-2.0%) was achieved within three months.
- Histologic analysis revealed new dense bone formation in bone specimens.
- Patients showed significant increases in total body bone mineral content (median, 28g) compared to predicted values.
- Improvements in growth velocity and a reduction in fracture frequency were observed.
Conclusions
- Allogeneic bone marrow transplantation facilitates the engraftment of functional mesenchymal progenitor cells.
- This strategy is feasible for treating osteogenesis imperfecta.
- The approach may also be applicable to other mesenchymal stem cell disorders.
View abstract on PubMed